友情链接
学术论坛

2020级研究生乐蕾、李嘉豪、NYAGWASWA ATHANAS MICHAEL、PHILIP SOGONOLI NDAKAMA做第209期研究生学术汇报


2021108日,山东大学护理与康复学院于学院105报告厅举行本学年第3期,总第209期学术论坛,本次学术论坛的汇报者分别为乐蕾、李嘉豪、NYAGWASWA ATHANAS MICHAELPHILIP SOGONOLI NDAKAMA,指导老师是郭玉芳老师。

第一位汇报者是2020级硕士研究生乐蕾,本次汇报的是发表在JAMA Network Open上的一篇文章,题为Association of Early-Life Adversity With Measures of Accelerated Biological Aging Among Children in China,该文章发表在Q1区,影响因子为8.483。该研究在中国青少年群体中运用进化发育框架探讨应激与生物衰老的关系,并探讨了基因-环境的交互作用。测量了一些反应青春期发育和生物老化的生理指标,比如乳房发育、端粒磨损。应激被分为两类:威胁和剥夺。结果提示应激(尤其是威胁)与加速生物老化有关,并且与青春期提前有关的基因调节了二者的关系。启示:1. 加速失效时间模型作为一个参数模型,可以同时计算风险比和时间比。用时间比来量化治疗效果时,具有一定的临床意义。也可用来预测数据“成熟”,比如,预测事件随着时间的推移如何累积;2. 应激的分类;3.未来可以从进化发育的角度探讨应激的影响。

 

第二位汇报者是2020级硕士研究生李嘉豪,本次汇报的是发表在Cell Metabolism杂志上的一篇文章,该杂志在2021年的影响因子是27.283。他汇报的文章题目是Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism,该研究主要从小鼠体内和足细胞中两个角度进行探索JAML是否通过加重足细胞的脂质积累从而促进了糖尿病肾病的发生和发展,采用了蛋白免疫印迹法、RT-PCR和免疫组织化学染色等方法,结果表明JAML可能是通过抑制Sirt-1--AMPK通路从而加重了肾脏脂质的积累。表明了JAML可能是治疗蛋白尿肾病的一个具有吸引力的潜在靶点。

 

The third reporter is Nyagwaswa Athanas Michael, a 2019 master's student. This report is an article published in The New England Journal of Medicine. The title of the article he reported is Prospective, Multicenter, Controlled Trial of Mobile Stroke Units.The study explored Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency medical services (EMS). But whether and how much MSUs alter outcomes has not been extensively studied. The study employed an observational, prospective, multicenter, alternating-week trial to assess outcomes from MSU or EMS management within 4.5 hours after onset of acute stroke symptoms. The main analysis involved dichotomized scores on the utility-weighted modified Rankin scale (0.91 or 1) at 90 days in patients eligible for t-PA.

The study enrolled 1515 patients, of whom 1047 were eligible to receive t-PA; 617 received care by MSU and 430 by EMS. The mean score on the utility-weighted modified Rankin scale at 90 days in patients eligible for t-PA was 0.72 in the MSU group and 0.66 in the EMS group (adjusted odds ratio for a score of 0.91, 2.43; 95% confidence interval [CI], 1.75 to 3.36; P=.001). Among all enrolled patients, the mean score on the utility-weighted modified Rankin scale at discharge was 0.57 in the MSU group and 0.51 in the EMS group (adjusted odds ratio for a score of 0.91, 1.82; 95% CI, 1.39 to 2.37; P=.001). Therefore, in patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS.

 

The forth reporter is Philip Sogonoli Ndakama, a 2019 master's student. This report is an article published in Clinical oncology.The title of the article he reported is The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.The study explored the MYC proto- oncogenes encode a family of transcription factors that are among the most commonly activated oncoproteins in human neoplasias. MYC aberrations or upregulation of MYC related pathways by alternate mechanisms occur in the vast majority of cancers. MYC proteins are master regulators of cellular programmes. Thus, cancers with MYC activation elicit many of the hallmarks of cancer required for autonomous neoplastic growth. In preclinical models, MYC inactivation can result in sustained tumour regression, a phenomenon that has been attributed to oncogene addiction. Many therapeutic agents that directly target MYC are under development; however, to date, their clinical efficacy remains to be demonstrated. In the past few years, studies have demonstrated that MYC signalling can enable tumour cells to dysregulate their microenvironment and evade the host immune response. This paper discussed how MYC pathways not only dictate cancer cell pathophysiology but also suppress the host immune response against that cancer. It also proposed that therapies targeting the MYC pathway will be key to reversing cancerous growth and restoring antitumour immune responses in patients with MYC driven cancers.

 

四位汇报者对相关学科领域的研究进行了精彩汇报,郭玉芳老师根据汇报内容进行了精彩点评,提出了许多宝贵的建议,大家受益匪浅,这一期学术论坛圆满结束。